

- genetic considerations in, 699t, 703  
*H. pylori* and, 536, 697, 703, 1038  
 in thymus, 123e-1  
 treatment of, 536, 703–704
- Mucosal bleeding, 404
- Mucosal malabsorption, 269
- Mucositis  
 acute necrotizing ulcerative (noma), 236, 487, 1097  
 chemotherapy-related, 103e-25  
 radiation therapy-related, 505  
 in transplant recipient, 139e-3
- Mucous retention cyst, oral, 240t
- Mu heavy chain disease, 719
- Muir-Torre syndrome, 365
- Muju virus, 1307t
- Mulberry molars, 236, 1137
- Muleshoe virus, 1308t
- Müllerian agenesis, 335, 336, 2357
- Müllerian epithelium, 592
- Müllerian inhibiting substance. *See* Antimüllerian hormone (AMH)
- Multicentric reticulohistiocytosis, 365
- Multidetector computed tomography (MDCT), 440e-1, 1664–1666. *See also* Computed tomography (CT)
- Multidrug resistance-associated protein 2 (MRP2), 2000
- Multidrug resistance-associated protein 3 (MRP3), 2000
- Multidrug resistance (MDR) phenotype, 102e-10
- Multifactorial disorders, 425, 440
- Multifactorial inheritance, 446
- Multifocal atrial tachycardia, 278e-5f, 1485, 1486f
- Multifocal motor neuropathy, 2696t, 2699
- Multifocal motor neuropathy with conduction block, 2633, 2636
- Multifocal visual evoked potentials, 442e-3
- Multi-infarct dementia, 2602
- Multikinase inhibitors, 102e-3–4, 102e-4f, 103e-18t, 103e-19
- Multilineage-differentiating stress-enduring cells, 453t
- Multilocus sequence typing, 769t
- Multinodular goiter, 2301–2302
- Multiorgan system failure, 1733
- Multiple carboxylase/biotinidase deficiency, 434e-3t
- Multiple endocrine and other organ neoplasias (MEONs), 2335  
 Carney's syndrome. *See* Carney's syndrome/complex  
 Cowden's syndrome. *See* Cowden's syndrome (multiple hamartoma syndrome)  
 McCune-Albright syndrome. *See* McCune-Albright syndrome  
 neurofibromatosis type 1. *See* Neurofibromatosis type 1 (NF1)  
 neurofibromatosis type 2. *See* Neurofibromatosis type 2 (NF2)  
 von Hippel-Lindau disease. *See* von Hippel-Lindau disease/syndrome
- Multiple endocrine neoplasia type 1 (MEN 1; Wermer's syndrome), 2335  
 clinical features of, 2335, 2336t  
 adrenocortical tumors, 2339–2340  
 angiofibromas, 364, 2340  
 collagenomas, 2340  
 gastrinoma, 1927–1928  
 glucagonoma, 2338  
 hyperparathyroidism, 2470  
 insulinomas, 2337–2338  
 lipomas, 2340  
 meningiomas, 2340  
 NETs, 562, 562t, 2339  
 neuropathy, 2685–2686  
 parathyroid tumors, 2335–2336, 2470  
 pituitary tumors, 2265–2266, 2265t, 2339  
 pNETs, 571, 2336, 2338–2339, 2338f  
 thyroid tumors, 2340  
 VIPomas, 2338  
 ZES, 562, 568, 2336–2337  
 epidemiology of, 2335
- genetic considerations in, 2340  
 chromosomes involved, 101e-6t, 562t, 2340, 2471, 2471f  
*MEN1/Menin* gene mutations, 599t, 2265–2266, 2265t  
 variable expressivity, 437  
 genetic testing in, 2340  
 pathogenesis of, 2251  
 screening tests in, 2337t, 2340
- Multiple endocrine neoplasia type 2 (MEN 2)  
 clinical features of, 2340  
 early interventions for, 450t  
 genetic considerations in, 101e-5, 2332, 2341t, 2342  
 genetic testing for, 449, 450t, 2342  
 medullary thyroid carcinoma in, 2332, 2332f, 2336t, 2340–2342. *See also* Medullary thyroid carcinoma (MTC)  
 medullary thyroid carcinoma only, 2307, 2336t, 2340–2342  
 parathyroid tumors in, 2342  
 pathogenesis of, 2251–2252  
 pheochromocytoma in, 2332, 2332f, 2342  
 screening tests in, 2341t, 2342
- type 2A  
 clinical features of, 365, 1619, 1620t, 2332, 2336t, 2340  
 genetic considerations in, 101e-6t, 2336t  
 hyperparathyroidism, 2470
- type 2B (MEN 3)  
 clinical features of, 436e-3f, 1619, 1620t, 2332, 2336t, 2340, 2470  
 genetic considerations in, 2336t
- Multiple endocrine neoplasia type 4 (MEN 4), 2265t, 2336t, 2342
- Multiple exostoses (diaphyseal aclasis), 426e-7
- Multiple hamartoma syndrome. *See* Cowden's syndrome (multiple hamartoma syndrome)
- Multiple/mixed valvular heart disease  
 clinical features of, 1551–1552  
 diagnosis of, 1552  
 pathophysiology of, 1550–1551  
 treatment of, 1552
- Multiple myeloma, 712  
 clinical features of, 713–714  
 amyloidosis, 721  
 bone lesions/pain, 102e-11, 119e-4, 713, 714f, 717  
 cardiac, 271e-6f, 271e-6v  
 cryoglobulinemia, 386e-5f  
 erythropoietin deficiency, 398  
 hypercalcemia, 610, 714  
 hypogammaglobulinemia, 486t, 492, 714  
 infections, 76e-12f, 484t, 486t, 713–714  
 neuropathy, 2685–2686, 2699–2700  
 paraneoplastic syndromes, 610, 618–619  
 proteinuria, 293  
 renal  
 contrast nephropathy, 1803, 1806t  
 light chain cast nephropathy, 62e-7f, 1805, 1859, 1859f  
 tubular damage, 714  
 diagnosis of, 81e-11f, 712f, 713f, 714–715, 715t, 2494  
 epidemiology of, 712–713  
 epigenetic changes in, 102e-7  
 etiology of, 712  
 genetic considerations in, 101e-2t, 712, 716  
 global considerations in, 713  
 immunology of, 698f  
 M component in, 715  
 nonsecretory, 715t  
 pathogenesis of, 102e-11, 713, 713f  
 prognosis of, 715–716, 716t  
 renal biopsy in, 62e-7f  
 as second malignancy in breast cancer, 529  
 smoldering, 715t  
 staging of, 715–716, 716t  
 treatment of  
 bortezomib, 102e-5t, 102e-6, 716–717  
 carfilzomib, 102e-5t  
 chemotherapy, 716–717  
 denosumab, 102e-11
- HSCT, 139e-5t, 139e-6, 717  
 lenalidomide, 716–717  
 relapsed disease, 717  
 supportive care, 717  
 thalidomide, 716–717  
 tumor markers in, 473t  
 von Willebrand disease in, 731
- Multiple sclerosis (MS), 2661  
 clinical features of, 41e-1v, 2663–2664, 2663t  
 constipation, 274  
 cranial nerve palsies, 2664  
 erectile dysfunction, 326  
 fatigue, 152  
 frontal lobe syndrome, 184  
 gait disorders, 163  
 hearing loss, 219  
 myelitis, 2656  
 myelopathy, 2659  
 ocular, 200, 202, 210, 2663  
 olfactory dysfunction, 214  
 paroxysmal, 2664, 2672  
 weakness, 156, 2663  
 clinical variants of, 2673  
 course of, 2664, 2664f  
 diagnosis of, 2664–2665, 2665t  
 differential diagnosis of, 2665, 2667t  
 epidemiology of, 2661–2662  
 genetic considerations in, 373e-8t, 444e-1, 444e-2, 2662  
 HLA gene association with, 373e-5, 373e-8t  
 imaging in, 441e-27–28f, 441e-35f, 2664–2665, 2666f  
 immunopathology of  
 autoimmunity, 372e-24t, 2662  
 autoreactive T cells, 2662  
 gut microbiota, 86e-8  
 inflammasome activity, 372e-8t  
 inflammatory mediators, 372e-29t  
 Marburg's variant, 2673  
 neurodegeneration in, 2662–2663  
 pathogenesis of, 444e-4f, 2661–2663, 2661f  
 pregnancy and, 49, 2666–2667  
 primary progressive, 2664, 2664f  
 prognosis of, 2665–2666  
 progressive/relapsing, 2664, 2664f  
 relapsing/remitting, 2664, 2664f  
 vs. sarcoidosis, 2208  
 scoring systems for, 2667, 2668t  
 secondary progressive, 2664, 2664f  
 treatment of, 2667  
 for acute attacks, 2667  
 alemtuzumab, 2669  
 dietary, 96e-7, 2672  
 dimethyl fumarate, 2669  
 experimental therapies, 444e-5, 2672–2673  
 fingolimod, 2669–2670  
 glatiramer acetate, 2668–2669  
 glucocorticoids, 2667  
 INF- $\beta$ , 2667–2668  
 for initial demyelinating episodes, 2667  
 initiation and changing of, 2670–2671, 2671f  
 mitoxantrone hydrochloride, 2669  
 natalizumab, 2669  
 off-label options in, 2672  
 outcomes of, 2669t  
 for progressive forms, 2671–2672, 2671f  
 for relapsing forms, 2667–2671, 2671f  
 symptomatic, 2672  
 teriflunomide, 2669  
 vitamin D supplements, 2671  
 triggers of, 2662
- Multiple sleep latency test, 188
- Multiple sulfatase deficiency, 432e-4t
- Multiple system atrophy (MSA)  
 clinical features of, 2612t, 2641  
 diagnosis of, 2610, 2612t  
 epidemiology of, 2641  
 imaging in, 441e-22f, 2641, 2641f  
 ocular involvement in, 196  
 parkinsonism in, 163, 2610, 2612t  
 prions in, 444e-10, 453e-6  
 treatment of, 2641
- Multiplex panels, 447